Difficulty: Easy
Correct Answer: Pharmaceutical production (biopharming/medical proteins)
Explanation:
Introduction / Context:Plants can be engineered to produce valuable therapeutic proteins. When genes for cytokines, clotting factors, or other human biologics are inserted into plant genomes, the resulting transgenic plants act as low-cost, scalable bioreactors. This strategy is commonly called molecular farming or biopharming.
Given Data / Assumptions:
Concept / Approach:The presence of therapeutic protein genes clearly points to pharmaceutical manufacture. While plants can also be engineered for nutrition, textiles, or fuels, cytokines and clotting factors are not nutrients, fibers, or fuels; they are biotherapeutics for treating disease.
Step-by-Step Solution:
Identify the type of gene: cytokines and clotting factors are therapeutic proteins.Match gene function to application: therapeutic proteins → pharmaceuticals.Select the most accurate and inclusive option: pharmaceutical production (biopharming).Verification / Alternative check:Case studies include plant-made clotting factor IX and cytokines produced in tobacco or cereal seeds for downstream purification, demonstrating feasibility and cost advantages.
Why Other Options Are Wrong:
Textile production: concerns fiber traits, not medical proteins.Vaccine production only: too narrow; plants can produce many biopharmaceuticals beyond vaccines.Nutrition improvement: relates to vitamins or minerals, not cytokines.Biofuel production: targets metabolic pathways for energy, not therapeutic proteins.Common Pitfalls:Confusing vaccine-only applications with broader biopharmaceutical production; overlooking that the same platform can produce antibodies, enzymes, and hormones.
Final Answer:Pharmaceutical production (biopharming/medical proteins).
Discussion & Comments